Laboratorio Reig Jofre, S.a. · BME:RJF
Laboratorio Reig Jofre — Q3 2021 Earnings Presentation
17 slides from Laboratorio Reig Jofre's earnings presentation, 2021
Slide 1: Results Third Quarter of 2021
RESULTS Third Quarter of 2021 1
Slide 2: Disclaimer
DISCLAIMER This presentation may contain forward-looking statements including statements about Reig Jofre’s intent, beliefs and expectations with respect to business and operations, market conditions, operating results and financial conditions, capital adequacy, specific provisions and risk manageme
Slide 3: Table of Contents
TABLE OF CONTENTS 01. 2021 RESULTS 02. PERFORMANCE OF THE BUSINESS UNITS 03. INCOME STATEMENT AND BALANCE SHEET 04. OUTLOOK FOR 2021 05. RJF SHARE PERFORMANCE PAGE 3
Slide 4: Q3 2021 Results Business Units
Q3 2021 RESULTS BUSINESS UNITS PAGE 4
Slide 5: Consolidated sales and EBITDA
REIG JOFRE's revenues grew by 2% up to September 2021 with 4% growth in its EBITDA SALES +2% The cumulative sales figure reached €173 million, exceeding the same period in 2020 by 2%. Recovery from the sale of prescription medical products from the Specialty Pharmacare division, and the good perfo
Slide 6: Revenues by Business Unit
Revenues by Business Unit PHARMACEUTICAL SPECIALTY CONSUMER TECHNOLOGIES HEALTHCARE PHARMACARE Antibiotics Energy Dermatology Injectables/Lyophilisates Stress and sleep Osteoarticular Slimming 44% € 76.2 million 31% € 54.0 million 25% Beauty OTC € 43.0 million -5% +9% +6% The Pharmaceutical Techno
Slide 7: Sales by Geographical Region
Sales by Geographical Region Rest of Rest of SPAIN EUROPE WORLD 45% 44% 11% European €77 . 4 million €76 . 1 million €19 . 7 million Union Rest of Europe 39% 5% Asia -3% + 7% -1% 6% Africa The Spanish market, as a whole, has resisted the sharp drop in the consumption of antibiotics and OTC disinfe
Slide 8: Income Statement and Balance Sheet
Q3 2021 INCOME STATEMENT BALANCE SHEET PAGE 8
Slide 9: Income Statement Q3 2021
Income Statement Q3 2021 2021/2020 Outlook A 2% increase in the sales figure accumulated up to September, with a gross margin remaining above 62% of sales, compared to 60% with which the same period of the previous year closed, by reducing the weight of essential medicines. The R & D capitalisat
Slide 10: Balance sheet: CAPEX 2021
Balance sheet Q3 2021 CAPEX 2021 14,1 € million R&D CAPITALISATION 3.2 million INDUSTRIAL CAPEX 10.9 million Industrial investments in technology and capacity increase stand at €10.9 million. The two main projects already initiated in previous periods are: an extensive renovation of the facilities
Slide 11: Balance sheet: Net financial debt
Balance sheet Q3 2021 NET FINANCIAL DEBT Debt|EBITDA 75,8 close of close of Q3 € million Q3 2,8 2021 2021 55,1 2020 2020 year- € million year- 2,1 end end FINANCIAL LEASE DEBT DEBT UNDER IFRS 16 12.1million 81.4million CORPORATE DEBT CREDIT AND OTHER 69.3million 11 Net financial debt has increased
Slide 12: Outlook for 2021
Q3 2021 OUTLOOK FOR 2021 PAGE 12
Slide 13: Outlook for 2021
Outlook for 2021 The third quarter of 2021 closes with a cumulative revenue growth of 2%, which reinforces our forecast to close the year on this sales growth-trend, but with different effects on the three business units. In the PHARMACEUTICAL TECHNOLOGIES division (44% of revenue), the decline in r
Slide 14: RJF Share Performance
Q3 2021 RJF SHARE PERFORMANCE PAGE 14
Slide 15: RJF Share Performance Oct '20 – Sept '21
RJF Share Performance Oct ’20 – Sept ’21 Market capitalisation of €352 million Data as at 30 September 2021 6,50 Cierre Close Close 6,25 31/12/20 31/12/20 30/09/21 6,00 5,75 4,39€ €4.39 €4.55 5,50 5,25 5,00 4,75 4,50 4,25 4,00 3,75 3,50 3,25 3,00 2,75 30/09 31/10 30/11 31/12 31/01 28/02 31/03 30/04
Slide 16: Links and Further Information
LINKS AND FURTHER INFORMATION LATEST NEWS https://www.reigjofre.com/en/news/ SUBSCRIPTION CENTRE https://www.reigjofre.com/en/news/subscription-center/ PAGE 16
Slide 17: Thank you
Table of Thank you Av. de les Flors 08970 Sant Joan Despi, Barcelona, Spain Tel. +34 93 480 67 10 www.reigjofre.com Investor Relations investors@reigjofre.com
Laboratorio Reig Jofre — Q3 2021 Earnings Presentation on 6ix